Immunocore (NASDAQ:IMCR – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday, Zacks reports.
IMCR has been the subject of several other reports. Morgan Stanley set a $43.00 target price on Immunocore in a report on Friday, August 7th. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Finally, Mizuho upped their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.
Read Our Latest Research Report on Immunocore
Immunocore Price Performance
Shares of NASDAQ:IMCR opened at $32.38 on Monday. Immunocore has a fifty-two week low of $27.50 and a fifty-two week high of $40.71. The business has a 50-day moving average of $31.46 and a two-hundred day moving average of $31.70. The stock has a market capitalization of $1.67 billion, a P/E ratio of -49.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.62 and a quick ratio of 4.44.
Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The company had revenue of $102.22 million for the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. On average, equities research analysts predict that Immunocore will post -0.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Alps Advisors Inc. boosted its position in shares of Immunocore by 32.7% in the third quarter. Alps Advisors Inc. now owns 68,246 shares of the company’s stock valued at $2,067,000 after acquiring an additional 16,826 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Immunocore during the third quarter worth $72,000. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 27.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock worth $285,000 after acquiring an additional 1,975 shares during the period. Crossmark Global Holdings Inc. raised its stake in Immunocore by 13.7% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 41,387 shares of the company’s stock valued at $1,254,000 after purchasing an additional 4,971 shares during the last quarter. Finally, Juncture Wealth Strategies LLC acquired a new position in Immunocore during the 3rd quarter valued at $207,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.
Immunocore News Summary
Here are the key news stories impacting Immunocore this week:
- Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
- Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
- Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
- Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
- Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.
About Immunocore
Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.
Further Reading
- Five stocks we like better than Immunocore
- The Trade Desk Beats on Revenue, But the Fine Print Matters
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
